Displaying all 2 publications

Abstract:
Sort:
  1. Beshir SA, Elnour AA, Soorya A, Mohamed AP, Goh SSL, Hussain N, et al.
    Saudi Pharm J, 2024 May;32(5):102047.
    PMID: 38596318 DOI: 10.1016/j.jsps.2024.102047
    [This corrects the article DOI: 10.1016/j.jsps.2023.101757.].
  2. Abdi Beshir S, Ahmed Elnour A, Soorya A, Parveen Mohamed A, Sir Loon Goh S, Hussain N, et al.
    Saudi Pharm J, 2023 Oct;31(10):101757.
    PMID: 37712012 DOI: 10.1016/j.jsps.2023.101757
    BACKGROUND: Recently, many drugs have been approved for halting overweight and obesity-few types of research shifted to using Anti-obesity medications (AOM) solely for well-being and shape-keeping.

    OBJECTIVE: This narrative review's objective was to explore the use of AOM in relation to their medical indications, efficacy, and cardiovascular safety.

    METHODS AND MATERIALS: We have conducted a narrative review of the literature on approved/non-approved AOM used for obesity and overweight. We have shed light on the emerging trials of therapies and evolving remedies.

    RESULTS: Recently, there has been an enormous change in the use of AOM with high consumption that deserves extensive surveillance for the long-term consequences and impact on social, mental, and physical health. Nearly six AOMs and combined therapy are approved by the Food and Drug Administration. The recent guidelines for obesity management have shifted the focus from weight loss to goals that the patient considers essential and toward targeting the root cause of obesity.

    CONCLUSION: The use of AOM increased enormously despite its sometimes-dubious safety and ineffectiveness. The public and medical professionals should be vigilant to the real-world benefits of anti-obesity drugs and their achieved effectiveness with an improved safety profile.

Related Terms
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links